Swedencare has in accordance with the agreement regarding the acquisition of the operations of Animal Pharmaceuticals, which was announced on September 24th 2020, paid an additional purchase price of approximately 87 million SEK.
The additional purchase consideration is based on the established EBITDA result of 2.7MUSD during the period July 2019 - June 2020 in the acquired business. The total purchase price for the business amounted to approximately 218 million SEK. The additional purchase price is financed partly from own funds and through a bank loan of 65 million SEK.
This information was distributed by MFN https://www.mfn.se/